Condition
Aluminum Allergy
Total Trials
4
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (4)
Trial Status
Completed3
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06529913Not ApplicableRecruiting
Environmental Exposure to Heavy Metals, Nanoparticles, and Emergent Contaminants and Risk of Allergic Diseases
NCT06130462Not ApplicableCompleted
Detection of Aluminium-reactive T-lymphocytes in Patients With Vaccination Granulomas
NCT04921163Not ApplicableCompleted
Children With Aluminium Contact Allergy: Oral Exposure Study
NCT04438135Not ApplicableCompleted
Children With Aluminium Contact Allergy: Cutaneous Exposure Study
Showing all 4 trials